Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ATAI

ATAI Life Sciences N.V

Mar 26 • 03:44PM ET

1.47

Dollar change -0.11
Percentage change -6.69	%

Healthcare • Biotechnology • Germany • NASD

Peers: CMPS MNMD GHRS CYBN RLMD SLS ANIX RGLS VNDA

| Held by: VHT PSIL GWX AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.80	Insider Own	32.31%	Shs Outstand	167.82M	Perf Week	5.40%
Market Cap	290.52M	Forward P/E	-	EPS next Y	-0.79	Insider Trans	24.13%	Shs Float	131.31M	Perf Month	-14.83%
Income	-128.60M	PEG	-	EPS next Q	-0.17	Inst Own	7.50%	Short Float	7.92%	Perf Quarter	23.11%
Sales	0.33M	P/S	880.36	EPS this Y	24.17%	Inst Trans	50.86%	Short Ratio	3.62	Perf Half Y	22.08%
Book/sh	0.87	P/B	1.69	EPS next Y	-11.31%	ROA	-50.86%	Short Interest	10.40M	Perf Year	-10.12%
Cash/sh	0.51	P/C	2.88	EPS next 5Y	17.72%	ROE	-62.43%	52W Range	1.03 - 2.85	Perf YTD	10.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.62%	ROI	-77.07%	52W High	-48.60%	Beta	1.19
Dividend TTM	-	Quick Ratio	5.81	Sales past 5Y	-13.20%	Gross Margin	-5.44%	52W Low	42.23%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	5.81	EPS Y/Y TTM	-89.51%	Oper. Margin	-31987.01%	RSI (14)	44.50	Volatility	8.68% 8.88%
Employees	54	Debt/Eq	0.16	Sales Y/Y TTM	-0.90%	Profit Margin	-38852.87%	Recom	1.00	Target Price	7.40
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	-157.61%	Payout	-	Rel Volume	0.73	Prev Close	1.57
Sales Surprise	-101.67%	EPS Surprise	-51.32%	Sales Q/Q	-54.02%	Earnings	Mar 17 BMO	Avg Volume	2.87M	Price	1.47
SMA20	-1.97%	SMA50	-13.90%	SMA200	2.10%	Trades		Volume	1,995,691	Change	-6.69%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Reiterated	H.C. Wainwright	Buy	$15 → $10
Apr-03-24	Upgrade	Maxim Group	Hold → Buy	$6
Nov-01-22	Initiated	Loop Capital	Buy	$18
Nov-30-21	Initiated	Maxim Group	Buy	$25
Nov-11-21	Initiated	ROTH Capital	Buy	$32
Oct-18-21	Initiated	H.C. Wainwright	Buy	$40
Sep-01-21	Initiated	Jefferies	Buy	$27
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform	$19
Jul-13-21	Initiated	Credit Suisse	Outperform	$25
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Citigroup	Buy	$26
Jul-13-21	Initiated	Cantor Fitzgerald	Buy	$45
Jul-13-21	Initiated	Canaccord Genuity	Buy	$28
Jul-13-21	Initiated	Berenberg	Buy	$35
Jul-08-21	Initiated	Aegis Capital	Buy	$26

Show Previous Ratings

Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks) +5.84%
Mar-17-25 08:00AM	atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks) +6.47%
Mar-11-25 07:00AM	atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression (GlobeNewswire)
07:00AM	Loading…
Mar-05-25 07:00AM	atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression (GlobeNewswire)
Mar-01-25 11:08AM	Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-24-25 04:10PM	atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -8.54% -5.49%
Feb-20-25 07:00AM	atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares (GlobeNewswire)
Feb-12-25 10:47PM	atai Life Sciences Announces Pricing of Public Offering of Common Shares (GlobeNewswire) +14.35% -10.98%
04:01PM	atai Life Sciences Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Feb-03-25 08:24AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) +19.35%
Jan-28-25 07:00AM	atai Life Sciences Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder (GlobeNewswire)
Jan-12-25 07:58PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
07:00AM	Loading…
Jan-10-25 07:00AM	atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health (GlobeNewswire) -7.41%
Nov-13-24 08:00AM	atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.53%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire) +12.06%
Oct-15-24 08:00AM	atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-04-24 07:00AM	atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 07:10AM	atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:00AM	atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT) (GlobeNewswire)
Aug-07-24 07:00AM	atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire) -5.11%
Jul-11-24 07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace) +10.61%
Jul-08-24 07:45AM	3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers (InvestorPlace)
Jul-06-24 07:21AM	3 Psychedelic Stocks to Ride to the Moon and Beyond (InvestorPlace)
Jul-03-24 09:48AM	Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns (InvestorPlace)
Jul-02-24 03:43PM	3 Psychedelic Stocks to Buy on the Dip: Summer 2024 (InvestorPlace)
Jun-26-24 07:00AM	atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference (GlobeNewswire)
06:09AM	atai Life Sciences co-CEO says initial results from ELE-101 show promise in treating depression (News Direct)
07:00AM	Loading…
Jun-20-24 07:00AM	atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a (GlobeNewswire)
May-31-24 07:00AM	atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference (GlobeNewswire) -6.55%
May-23-24 07:00AM	atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors (GlobeNewswire)
May-15-24 12:54PM	ATAI Stock Earnings: ATAI Life Sciences Beats EPS for Q1 2024 (InvestorPlace) +7.33%
06:59AM	atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Apr-24-24 07:00AM	atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression (GlobeNewswire) -5.08%
Apr-17-24 07:00AM	atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology (GlobeNewswire) -7.91%
Mar-28-24 07:00AM	atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights (GlobeNewswire) +10.06%
Mar-27-24 07:00AM	atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression (GlobeNewswire)
Mar-19-24 08:00AM	The Next Great Biotech Boom Has Arrived (PR Newswire)
Mar-12-24 12:35PM	atai Life Sciences advances VLS-01 for treatment-resistant depression (News Direct) -5.45%
Mar-04-24 08:00AM	atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01 (GlobeNewswire)
Feb-28-24 05:00PM	atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-06-24 05:00PM	atai Life Sciences Appoints Anne Johnson as Chief Financial Officer (GlobeNewswire) -5.03%
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire)
Jan-07-24 10:15PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-05-24 08:54AM	Ecstasy-for-Medicine Advocate Raises $100 Million (The Wall Street Journal)
08:00AM	Legalization Advocate MAPS Raises Money for Pharmaceutical Psychedelics (The Wall Street Journal)
Jan-04-24 07:00AM	atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics (GlobeNewswire) +14.67%
Jan-02-24 08:00AM	atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA) (GlobeNewswire) +19.86%
Nov-14-23 07:03AM	atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights (GlobeNewswire) +9.13%
Oct-15-23 05:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-10-23 08:00AM	ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT (PR Newswire)
Oct-06-23 04:05PM	atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit (GlobeNewswire) -8.55%
Oct-02-23 04:13PM	atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants (GlobeNewswire) +12.10%
Sep-14-23 11:02PM	Insider Buying: Florian Brand Acquires 40,000 Shares of ATAI Life Sciences NV (GuruFocus.com)
08:02AM	atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-06-23 04:01PM	atai Life Sciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-10-23 06:59AM	atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) (GlobeNewswire)
Aug-08-23 04:02PM	atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) (GlobeNewswire)
Jun-28-23 09:37AM	Ecstasy-for-Medicine Advocate Seeks Cash Lifeline (The Wall Street Journal) +7.89%
Jun-01-23 09:10AM	Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
06:59AM	atai Life Sciences to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-11-23 06:59AM	atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates (GlobeNewswire)
May-02-23 05:20PM	atai Life Sciences to Participate in Upcoming May Investor Conference (GlobeNewswire)
Apr-28-23 06:59AM	atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting (GlobeNewswire)
Apr-13-23 06:59AM	atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) (GlobeNewswire) +9.89%
Apr-03-23 07:00AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research) +13.12%
Mar-24-23 06:59AM	atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights (GlobeNewswire) +5.04%
Mar-06-23 07:00AM	atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates (GlobeNewswire)
Mar-01-23 04:01PM	atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Jan-19-23 01:24PM	This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks (Benzinga)
Jan-17-23 05:00AM	Trippy Trading: Top Psychedelic Stocks For 2023 (News Direct) +7.78%
Jan-09-23 07:00AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -9.34%
06:59AM	atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917 (GlobeNewswire)
Jan-06-23 10:38AM	Atai Life Sciences' Depression Candidate Faces Trial Setback, Shares Nosedive (Benzinga) -30.80%
07:00AM	atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression (GlobeNewswire)
Dec-23-22 06:59AM	atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101 (GlobeNewswire) -12.17%
Dec-19-22 06:59AM	atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia (GlobeNewswire)
Dec-16-22 10:00AM	The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital (GlobeNewswire)
Dec-01-22 07:39PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -5.38% +6.29%
Nov-29-22 06:59AM	atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer (GlobeNewswire)
Nov-17-22 07:00AM	atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment (GlobeNewswire)
Nov-10-22 06:59AM	atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update (GlobeNewswire) +7.72%
Nov-04-22 09:35AM	Women in Psychedelics Announces atai as Platinum Sponsors (Business Wire)
Nov-01-22 12:00PM	atai Life Sciences to Participate in November Investor Events & Healthcare Conferences (GlobeNewswire) +14.58%
07:00AM	atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Oct-25-22 07:03AM	atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression (GlobeNewswire)
Oct-20-22 06:59AM	atai Life Sciences Announces R&D Day Agenda (GlobeNewswire) +7.60%
Oct-18-22 07:00AM	atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology (GlobeNewswire)
Oct-13-22 09:21AM	IntelGenxs Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate (GlobeNewswire)
Oct-12-22 07:00AM	atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD (GlobeNewswire)
Oct-05-22 07:00AM	atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT (GlobeNewswire)
Oct-04-22 07:00AM	atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day (GlobeNewswire)
Sep-27-22 08:00AM	atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01 (GlobeNewswire) +7.96%
Sep-06-22 06:30PM	atai Life Sciences to Participate in September Investor Events (GlobeNewswire)
Aug-15-22 07:35AM	atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update (GlobeNewswire)
06:55AM	atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital (GlobeNewswire)
Aug-01-22 06:59AM	atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update (GlobeNewswire) -8.03%

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kirpekar Sahil	Chief Business Officer	Mar 21 '25	Sale	1.35	48,563	65,560	115,636	Mar 24 09:00 PM
Craig Kevin James	Chief Medical Officer	Mar 21 '25	Sale	1.35	11,563	15,610	8,437	Mar 24 09:00 PM
Rao Srinivas	See Remarks	Mar 21 '25	Sale	1.35	75,418	101,814	212,942	Mar 24 09:00 PM
Johnson Anne Nagengast	Chief Financial Officer	Mar 21 '25	Sale	1.35	33,545	45,286	140,045	Mar 24 09:00 PM
Short Glenn Frank	Chief Scientific Officer	Mar 21 '25	Sale	1.35	13,161	17,767	42,333	Mar 24 09:00 PM
FLORIAN BRAND	Officer	Mar 24 '25	Proposed Sale	1.54	100,000	154,090		Mar 24 05:10 PM
Apeiron Investment Group Ltd.	10% Owner	Mar 24 '25	Buy	1.40	1,800,000	2,520,000	42,369,415	Mar 24 05:00 PM
Brand Florian	Former Officer	Mar 19 '25	Proposed Sale	1.39	184,451	256,387		Mar 21 06:49 PM
Craig Kevin James	Officer	Mar 21 '25	Proposed Sale	1.39	11,563	16,073		Mar 21 06:46 PM
Short Glenn Frank	Officer	Mar 21 '25	Proposed Sale	1.39	13,161	18,294		Mar 21 06:42 PM
Johnson Anne Nagengast	Officer	Mar 21 '25	Proposed Sale	1.39	33,545	46,628		Mar 21 06:39 PM
Rao Srinivas	Officer	Mar 21 '25	Proposed Sale	1.39	75,418	104,831		Mar 21 06:35 PM
Kirpekar Sahil	Officer	Mar 21 '25	Proposed Sale	1.39	48,563	67,503		Mar 21 06:32 PM
FLORIAN OLAF BRAND	Officer	Mar 20 '25	Proposed Sale	1.38	300,000	412,560		Mar 20 04:39 PM
Apeiron Investment Group Ltd.	10% Owner	Feb 14 '25	Buy	2.10	10,835,718	22,755,008	40,555,215	Feb 19 06:00 PM
ATAI Life Sciences N.V.	10% Owner	Sep 26 '24	Sale	6.05	2,660,000	16,093,000	6,905,774	Sep 27 08:00 PM
Brand Florian	See Remarks	May 16 '24	Sale	1.92	151,303	290,502	328,697	May 20 05:30 PM
Johnson Anne Nagengast	Chief Financial Officer	Apr 02 '24	Sale	1.85	27,410	50,708	73,590	Apr 04 06:11 PM
Rao Srinivas	See Remarks	Apr 02 '24	Sale	1.85	61,640	114,034	113,360	Apr 04 06:11 PM
Kirpekar Sahil	Chief Business Officer	Apr 02 '24	Sale	1.85	35,801	66,232	64,199	Apr 04 06:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATAI

ATAI Life Sciences N.V

Upgrade your FINVIZ experience